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Key Points
• Unusual sugars on the tips of
sIg of FL cells interact with
a tissue lectin to activate
tumor-specific signaling.
• Activating lectin does not
allow endocytosis of sIg,
leading to persistent, essential,
and targetable antigen-
independent stimulation.
The vast majority of cases of follicular lymphoma (FL), but not normal B cells, acquire
N-glycosylation sites in the immunoglobulin variable regions during somatic hyper-
mutation.Glycans added to sites are unusual in terminating at highmannoses.We showed
previously that the C-type lectins, dendritic cell–specific intercellular adhesion molecule-3
grabbingnon-integrin (DC-SIGN)andmannosereceptor,boundtoFLsurface immunoglobulin
(sIg), generatingan intracellularCa21 flux.Wehavenowmapped further intracellularpathways
activatedbyDC-SIGN ina rangeofprimaryFLcellswithdetectionof phosphorylatedERK1/2,
AKT, and PLCg2. The SYK inhibitor (tamatinib) or the BTK inhibitor (ibrutinib) each
blocked phosphorylation. Activation byDC-SIGN occurred in both IgM1 and IgG1 cases and
led to upregulation of MYC expression, with detection in vivo observed in lymph nodes.
Unlike cells of chronic lymphocytic leukemia, FL cells expressed relatively high levels of
sIg, unchanged by long-term incubation in vitro, indicating no antigen-mediated down-
regulation in vivo. In contrast, expression of CXCR4 increased in vitro. Engagement of sIg in
FLcellsornormalBcellsbyanti-Ig led toendocytosis in vitro asexpected, butDC-SIGN, evenwhencross-linked, didnot lead tosignificant
endocytosis of sIg. These findings indicate that lectin binding generates signals via sIg but does not mediate endocytosis, potentially
maintaininga supportive antigen-independent signal in vivo. LocationofDC-SIGN inFL tissue revealedhigh levels in sinusoidlike structures
and in some colocalized mononuclear cells, suggesting a role for lectin-expressing cells at this site. (Blood. 2015;126(16):1902-1910)
Introduction
It is known that the t(14;18) translocation found in themajority of cases
of FL, which leads to upregulation of BCL2 expression, is necessary
but not sufﬁcient for tumor development.1 Although further genomic
changes are being revealed, particularly in histone-modifying genes,2
the role of the microenvironment is also likely to be critical.3 Another
important feature of FL is that, despite the loss of one Ig allele by the
t(14;18) translocation, surface immunoglobulin (sIg) is retained. Ini-
tially this retention and the ongoing somatic hypermutation (SHM)
led to speculation about a role for persistent antigen in FL, whichwas
difﬁcult to explain, given the high variability of IGV gene usage and
the sequence changes resulting fromSHM.A striking observation on
the nature of sIg in FL has revealed a possible explanation both for
retention of sIg and for an inﬂuence of microenvironmental factors.
This involves a “universal” antigen-independent mechanism able to
engage sIg of all cases of FL.4 Speciﬁcally, in FL there is a tumor-
speciﬁc structural change of sIg variable regions by introduction of
motifs forN-addition of unusual glycans.5,6 The placement of these
glycans at the tip of the sIg on FL cells not only provides a common
molecular feature for interaction with lectin, but, also allows
a functional bridge between the sIg and the microenvironmental
cells that express candidate lectins.4
The introduced glycosylation motifs are in the sIg variable regions
of most, if not all, FL cases, but are rare in normal B cells.7 Motifs are
generated during SHMand appear to be positively selected by FL cells.
They are also maintained over time, even while SHM continues,8 in-
dicating an important role in pathogenesis and maintenance in the ger-
minal center (GC) site. There is additional evidence for acquisition of
motifs in otherGC-locatedB-cellmalignancies suchas endemicBurkitt
lymphoma, and a proportion of diffuse large B-cell lymphoma, but not
in multiple myeloma, mucosa-associated lymphoid tissue lymphomas,
or mutated chronic lymphocytic leukemia (CLL).9
We showed previously that the glycan added to the sites is unusual
in terminating at the highmannose stage.5 In contrast, available sites in
the constant region are fully N-glycosylated,10 suggesting that the mo-
tifs in the IGHV region, although present at various sequence positions,
and sometimes in IGLV, are sterically unavailable for glycosyl trans-
ferase activity in the Golgi. The outcome is expression in all cases of
sIg, with mannosylated sites in the V regions and fully glycosylated
sites in the constant region.4,5
Candidate lectins in lymphoid tissue able to interact with FL sIg
include dendritic cell–speciﬁc intercellular adhesion molecule-3
grabbing non-integrin (DC-SIGN) and mannose receptor.11 These are
Submitted April 15, 2015; accepted July 9, 2015. Prepublished online as Blood
First Edition paper, July 20, 2015; DOI 10.1182/blood-2015-04-640805.
*A.L. and S.K. contributed equally to this study.
†G.P. and F.K.S. contributed equally to this study.
The online version of this article contains a data supplement.
There is an Inside Blood Commentary on this article in this issue.
The publication costs of this article were defrayed in part by page charge
payment. Therefore, and solely to indicate this fact, this article is hereby
marked “advertisement” in accordance with 18 USC section 1734.
© 2015 by The American Society of Hematology
1902 BLOOD, 15 OCTOBER 2015 x VOLUME 126, NUMBER 16
For personal use only.on April 28, 2016. by guest  www.bloodjournal.orgFrom 
both calcium-dependent (C-type) lectins with a major role in
innate immunity, being able to bind to mannoses expressed by
a range of pathogens and by self-ligands.12 Both recombinant
proteins were also able to bind to the mannosylated sIg and induced
a tumor-speciﬁcsIg-mediated intracellular [Ca12]ﬂux inprimaryFLcells,
with no signal in normal B cells. A control protein, consisting of
mannose receptor with the carbohydrate-recognition domain re-
moved, was used to conﬁrm the speciﬁcity for binding to glycan
expressed by FL cells. A blocking experiment using mannosylated or
nonmannosylated single-chain Fv indicated binding to mannosylated
sIgM.4 We have now focused on DC-SIGN as a paradigm and have
analyzed the intracellular pathways activated by binding of either the
soluble lectin or after attachment to beads. Exposure of sIgM1or sIgG1
FLcases to either formofDC-SIGNinducedphosphorylationofERK1/2,
PLCg, and AKT. Bead-bound DC-SIGN also increased levels of MYC,
withMYCproteindetected inFL lymphnodes. In contrast, normalBcells
that express similar levels of sIg failed to respond to DC-SIGN. Another
intriguingﬁndingwas that,unlike anti-Ig, solubleDC-SIGN,evenwhen
crosslinked, did not mediate signiﬁcant endocytosis of sIg. These
features may have been captured by opportunistic FL cells for long-
term survival and proliferation in the hostile GC site.
Methods
Patient and healthy donor material
Primary cells from lymph nodes of 18 FL patients and peripheral blood
mononuclear cells from the blood of 5 healthy donors were isolated from
frozen stocks.7 Approval was obtained from the Southampton and South
West Hampshire Research Ethics Committee and informed consent was
obtained in accordance with the Declaration of Helsinki. Cells were rapidly
thawed at 37°C before puriﬁcation of viable cells using Lymphoprep. After
washing in complete medium (RPMI 1640 medium supplemented with
10% [vol/vol] fetal calf serum, 2 mM glutamine, and 1% [wt/vol] sodium
pyruvate) and counting using Trypan Blue exclusion, cells were allowed to
rest for 30 minutes at 37°C/5% CO2.
Phenotype and IGHV sequences
Live FL cells were analyzed using anti-IgM-R-Phycoerythrin (PE), anti-IgD-
ﬂuorescein isothiocyanate (FITC), anti-IgG-FITC (all DAKO, Ely, United
Kingdom [UK]), anti-humanCD19 Paciﬁc Blue or allophycocyanin (APC), and
anti-humanCD5PerCP/Cy5.5 (BioLegend,Cambridge,UK).Cellswere labeled
with anti-IgM/IgD/CD19/CD5 or anti-IgM/IgG/CD19/CD5 or corresponding
isotype controls. Surface Ig expression was measured in CD191/CD5– popu-
lation.Sampleswere acquiredonaFACSCanto II (BDBiosciences,Oxford,UK).
BCL21FLcellswere identiﬁed for immuneﬂuorescent analysis afterﬁxation
in paraformaldehyde (ﬁnal concentration 1.6%) (VWR, Lutterworth, UK). Cells
were incubated for 5 minutes at room temperature, washed and resuspended in
ice-cold 90% (vol/vol)methanol, and incubated on ice for 30minutes. Then cells
werewashed and reconstituted in FlowBuffer (1%bovine serumalbumin, 4mM
ethylenediamine tetraacetic acid (EDTA), and 0.15 mM NaN3 in phosphate-
buffered saline). Staining was done with directly labeled anti-CD20 PerCP-Cy
5.5 (clone H1/FB1), anti-BCL2-FITC (clone 6C8). Samples were acquired on a
FACSCanto II. Gatingwas ﬁrst for singlets (FSC-H/FSC- A), then lymphocytes
(SSC-A/FSC-A) before gating based on CD20 and BCL2 double-positivity.
Tumor-derived IGV(D)J gene sequences were identiﬁed in FL samples as
described.7
DC-SIGN, anti-Ig, and bead conjugation
Recombinant human DC-SIGN/CD209-Fc chimera (soluble DC-SIGN) (R&D
Systems,Abingdon,UK) comprises the dimeric extracellular portion (aa64-404)
covalently linked to human Fcg, goat F(ab9)2 anti-m, anti-g, or goat F(ab9)2
isotype control (Southern Biotech, Cambridge Biosciences UK), which were
used as soluble proteins or were each conjugated to Dynabeads M-280, 2.8-mm
diameter, with epoxy surface groups (Invitrogen, Paisley, UK) according to the
manufacturer’s instructions. Brieﬂy, beads were washed in the provided C1
buffer, and proteins were added at 10 mg per mg of beads. The suspension was
incubated on a rotator at 37°C overnight, then washed in the provided C2 buffer
and resuspended in the provided SB storage buffer at a ﬁnal bead concentration
of 10mg beads permL so that 1.5mL includes 106 beads. For long-term storage,
0.02% NaN3 was added.
Binding of DC-SIGN to surface Ig on primary FL
FL cells were divided into ﬂuorescence-activated cell sorting (FACS) tubes
and were placed on ice before treatment with soluble DC-SIGN. Tubes were
incubated on ice for 45 minutes before 4% paraformaldehyde was applied to
ﬁx cells at room temperature for 15 minutes. Cells were washed twice in
phosphate-buffered saline and centrifuged at 1500 rpm for 5minutes and then
resuspended in Flow Buffer. To determine the level of DC-SIGN binding, a
monoclonal mouse anti-human-CD209 IgG2b antibody (BD Biosciences)
was added and incubated at room temperature for 45 minutes. As a control,
some cells were not treated with antibody. Cells were washed and resus-
pended using Flow Buffer before the addition of Alexa Fluor488-conjugated
goat anti-mouse-IgG Fcg2b (Jackson ImmunoResearch, Newmarket, UK) to
detect bound anti-CD209 or Dylight549-conjugated goat anti-human IgM
(Jackson ImmunoResearch) to detect sIgM. Tubes were incubated at room
temperature in darkness for 30minutes then washed and resuspended in Flow
Buffer before analysis with a BD FACSCanto. Data were analyzed using
FlowJo (Tree Star, Ashland, OR). Singlet live cells were gated on to detect
sIgM expression, and cells positive for this were gated on to determine DC-
SIGN binding.
To ensure that binding was unaffected by the Fc portion of the DC-SIGN
molecule potentially attaching to FcgRIIb, we masked this receptor by 2 strat-
egies. First, using the AT10 antibody,13 and second, using an FcR-blocking
reagent (Miltenyi Biotec, Surrey, UK). Cells were treated on ice for 10 minutes
with either 100mg/mLAT10orFcR-blocking reagent, per themanufacturer’s in-
structions. After washing in complete medium, the binding protocol was carried
out as described.
Immunoblot analysis
Immunoblotting was performed as described14 using: anti-phospho-ERK1/2
(9101), anti-ERK1/2 (9102), anti-phospho-AKT (S473) (4060), anti-AKT (9272)
(all fromCell Signaling Technology, Hitchin, UK), anti-MYC (clone 9E10)
(Merck Millipore, Beeston, UK), and anti-b-actin (2066; Sigma-Aldrich, Poole,
UK).Secondary horseradish peroxidase-conjugated antibodies were obtained
fromGEHealthcare (Little Chalfont, UK). Imageswere collected using a Fluor-S
MultiImager (BioRad, Hemel Hempstead, UK) and quantiﬁed using Fluor-S
softwareQuantityOneVersion 4.6.3 (BioRad).All valueswere normalized to the
relevant loading control, and relative fold change was calculated with the isotype
control antibody-treated cells taken as a 1.0 fold of expression.
PhosFlow analysis
For the PhosFlow assay,15 FL cells were left in completemedium for 60minutes
to recover at 37°C.0.5 to13106 cells in0.1mLofmediumwere left untreatedor
treatedwith anti-Igmix (10mg/mLgoatF[ab9]2 anti-human IgMandanti-human
Fcg) or DC-SIGN (10 mg/mL) crosslinked with anti-human IgG (Fc-speciﬁc),
F(ab9)2 antibody (Sigma-Aldrich) (DC-SIGN:anti-IgG [3:1molar ratio] to avoid
nonspeciﬁc binding from anti-IgG in the experiment, 30 min preincubation) for
indicated time points. H2O2 was added immediately before stimulation at a ﬁnal
concentration of 3.3mM,15 except for one unstimulated control. Stimulationwas
stopped by the addition of paraformaldehyde (ﬁnal concentration 1.6%) (wt/vol),
and cells were incubated for 5 minutes at room temperature and then washed
and resuspended in ice-cold 90% (vol/vol) methanol and incubated on ice for
30 minutes. Then cells were washed and reconstituted in Flow Buffer and stain-
ed with directly labeled anti-CD20 PerCP-Cy™ 5.5 (clone H1/FB1), anti-
BCL2-FITC (clone 6C8), anti-ERK1/2 (pT202/pY204)-PE or PLC-g2 (pY759)
Alexa Fluor 647, or appropriate isotype controls antibodies (all from BD Bio-
sciences) for 30 minutes on ice and then washed and reconstituted in the Flow
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Buffer. Samples were acquired on a FACSCanto II. Change in phosphorylation
was determined on the gated CD201/Bcl21 cells, and geometric mean ﬂuores-
cence intensity (GeoMFI) was calculated for PE (pERK) or Alexa Fluor 647
(pPLC-g2) at the different time points. The results were analyzed by the online
analytical platformCytobank (Cytobank, Inc.,MountainView, CA). The resulting
GeoMFIwere normalized to controls samples (H2O2 treatment only) for each time
point and fold changes in phosphorylation were calculated.
Immunohistochemistry
4-m-thick formalin-ﬁxed, parafﬁn-embedded sections obtained from reac-
tive tonsils and follicular lymphomas (encompassing grades 1, 2, and 3a)
were stained with the following antibodies: CD20 (clone L26, Dako, Glostrup,
Denmark; dil. 1:100),CD21 (cloneEP3/93, cellMarque,Rocklin,CA; dil. 1:50),
c-MYC (clone Y69Abcam, Cambridge, UK; dil. 1:200), and CD209 (clone
EPR5588,Epitomics,Burlingame,CA; dil 1:100). ForCD20,CD21, and c-MYC
antibodies, antigen retrievalwas obtainedwithTris-EDTAat pH9 for 30minutes.
CD209 and corresponding double stains were performed on frozen sections.
Kinase inhibitors
The clinical BTK and SYK inhibitors ibrutinib and tamatinib (the active form
of fostamatinib) (Stratech Scientiﬁc Ltd, Suffolk, UK) were used at 10-mM
ﬁnal concentration. Cells were pretreated with the inhibitor for 30 minutes
before stimulation.
Endocytosis of surface immunoglobulin
Internalization of sIgM was assessed by measuring the remaining anti-Ig or
DC-SIGN on the cell surface of CD191ve cells with secondary FITC-labeled
antibodies. Brieﬂy, washed and precooled cells were preincubated with
20 mg/mL goat F(ab9)2 anti-human Ig or DC-SIGN for 40 minutes on ice.
Aliquots (13 106 cells) were left for the unstained control and the secondary
antibody controls. Then the cells labeled with anti-Ig or DC-SIGN and were
divided into aliquots (13 106 cells) for incubation on ice or at 37°C for 0, 10,
30, and 60 minutes. At each time point, internalization was stopped by the
addition of ice-cold Flow Buffer and cells were left on ice. Next, cells were
washed in ice-cold Flow Buffer and labeled with anti-CD19-APC and rabbit
anti-goat F(ab9)2-FITC (Jackson ImmunoResearch,) for anti-Ig labeled cells
or goat anti-human IgM secondary antibody, and FITC (Cambridge Bioscience,
Cambridge, UK) for DC-SIGN–labeled cells. Samples were acquired on a
FACSCanto II and GeoMFI for the green channel in CD191ve gated cells were
used to calculate percentage of internalization. The GeoMFI value at time 0 was
used as 100% of sIg expression.
Results
Primary FL tissue analysis
The primary FL samples investigated were from lymph nodes of 18
cases of grades 1-3a (supplemental Table 1, available on the BloodWeb
site) and included 12 IgM1 and 6 IgG1 cases by phenotype. Analysis of
the IGHVHDHJ-constant region by polymerase chain reaction analysis
conﬁrmed the isotype and revealed Asn-X-Ser/Thr motifs in 13 of 13
cases, with 6 of these having additional sites in IGLV. All cases of FL
where clonal sequences of both IGHV and IGLV were analyzed had
motifs. Sampleswere analyzed for tumor cells byCD20/BCL2 staining
(Figure 1A) and expression of surface Ig with representative IgM1 or
IgG1 cases shown in Figure 1B. The percentage of B cells in themono-
nuclear cell fraction was usually 40% to 50% and the proportion of
normal (BCL2–) cells in the B-cell population was low (;10%-20%).
DC-SIGN binds to primary FL cells and specifically activates
signaling pathways
Primary FL cells express relatively high but variable levels of sIg. We
compared the level of binding of DC-SIGN with the amount of ex-
pressed sIg in 6 cases of sIgM1 FL. Results on 3 cases are illustrated
in Figure 2A and controls using either an Fcg RIIb–blocking antibody
(AT10)13 or the commercial FcR blocker showed that binding was
speciﬁc for the DC-SIGN component of DC-SIGN-Fc (Figure 2B).
Data from the 6 patients indicated correlation between sIgM levels
and binding of DC-SIGN (Figure 2C). In 2 cases (774 and 861) (sup-
plemental Figure 1), we detected 2 populations of BCL21 cells express-
ingdifferent (highand low) levelsof sIgM(supplementalFigure1A), and
in a further case (590) there was a broad peak indicating a range of sIgM
expression.Analysisof thesesamplesforDC-SIGNbindingshoweddou-
ble peaks (supplemental Figure 1B), and back-gating to determine the
level of sIgM on the peaks revealed a correlation between DC-SIGN
binding and the level of sIgMexpression (supplemental Figure 1C). This
supports the conclusion that DC-SIGN is binding to sIgM and that the
ability to bind varies with the level of sIgM expression. However, in
addition to sIgM levels, another variable is the number of glycan addition
sites permolecule. Some correlationwith binding is apparent, with cases
86 and 590 having 5 and 3 sites, respectively (Figure 2C), but case 221
with 4 sites was an exception being only a moderate binder, perhaps
indicating heterogeneity in glycan addition.
Figure 1. Characterization of FL cells. Phenotyping of
representative patients used in this study, including FACS
plots detailing gating strategy of singlet CD201 cells to
determine BCL2 expression (A) and gating of singlet, live
CD191 FL cells expressing to determine IgM (FL334) or
IgG (FL45) isotype (B).
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Exposure of primary FL cell samples to DC-SIGN led to phos-
phorylation of ERK1/2 and AKT. The level of constitutive phosphor-
ylation before stimulation is difﬁcult to estimate, especially because
phosphorylation can be reversed by cellular phosphatases during the
processing of tissue samples. In contrast, phosphorylation induced by
DC-SIGN in vitro is clear and occurred in both IgM1 (Figure 3A) and
IgG1 cases (Figure 3B). The level of response induced by bead-bound
DC-SIGNwas generally higher than the soluble form. Again, blocking
of the FcR had no effect on responses, indicating speciﬁcity for
DC-SIGN (supplemental Figure 2). Increasing the bead:cell ratio to 4:1
did generate higher responses against DC-SIGN, which was especially
evident with p-AKT (supplemental Figure 2). Because DC-SIGN is
a calcium-dependent lectin, we measured responses in 2 cases over a
rangeof calciumconcentrations and found that the level inmediumplus
FCS (1.5 mM) was adequate (supplemental Figure 3); therefore, this
was used in all experiments.
Comparative data showing stimulation with DC-SIGN or with
anti-Ig on 16 cases are illustrated in Figure 3C. Although responses to
anti-Ig are higher, the responses to DC-SIGN appear to persist longer,
with little reduction from 0.5 to 6 hours. In contrast to primary FL cells,
normal B cells did not respond to bead-bound DC-SIGN, although the
response to anti-Ig was similar to FL cells (Figure 3D). The gel shows
one example of the same results obtained from 4 normal donors, using
circulatingBcells.Becauseof very small numbers,15 itwas not possible
to investigate the normal B cells remaining in the tissue sites.
Analysis of responses to DC-SIGN in single FL cells
Responses of single cells were analyzed by ﬂow cytometry using sol-
uble DC-SIGN crosslinked via anti-Fcg. Soluble anti-Ig was used as
a control, and detection of responses was done by PhosFlow using
FITC-labeled antibodies against either p-ERK or p-PLCg. The basal
phosphatase activity was inhibited by the addition of hydrogen
peroxide.15A typical result (Figure 4A) using an IgG1 sample (FL-33),
gated on CD20 and BCL-2 double-positive expression, conﬁrms the
early phosphorylation of ERK seen by western blotting, with a similar
pattern observed for PLCg. No change in cell size was observed after
either stimulus.
We constructed heat maps of scalable geometric means of re-
sponses for 13 FL cases. Compared with the unstimulated controls
(NT), all cases responded, but at variable levels (supplemental
Figure 4A). Higher responses to DC-SIGN were generally found in
cells with higher responses to anti-Ig. The non–B-cell fraction,
mainly T cells, gave only background (;9%pPLCg2 level and;6%
p-ERK level) of maximal responses for FL cells when exposed to
DC-SIGN (data not shown).
Compiled kinetic responses of FL cells to lectin are similar to those
with anti-Ig, but again tended to be more persistent (Figure 4B). We
could ﬁnd no consistent signiﬁcant differences in the level of phos-
phorylation between IgM1 or IgG1 cases (supplemental Figure 4B),
although numbers are limited.
Inhibitors of B-cell receptor–associated proximal kinases
decrease DC-SIGN–dependent signaling in FL
We then tested whether inhibitors of SYK (tamatinib) or BTK
(ibrutinib) acted against pathways stimulated in FL cells viaDC-SIGN.
Analysis by single-cell ﬂow cytometry for the effects of pre-exposure
to inhibitor for 30 minutes on signaling showed strong inhibition of
responses against either anti-Ig orDC-SIGN.Compiled data for 6 cases
(SYK) and 3 cases (BTK) are shown in Figure 4C.
DC-SIGN stimulates MYC expression in primary FL cells
To investigate the downstream B-cell receptor–associated targets acti-
vated by DC-SIGN, we analyzed MYC expression in FL. Basal levels
ofMYCweremostly low,butwere increasedbyexposure to bead-bound
DC-SIGN(2 representativeexamples shown inFigure5A).The response
was again weaker than that induced by bead-bound anti-Ig but had
Figure 2. DC-SIGN binding to surface IgM1 primary
FL cells. Representative FACS plots of 3 FL samples
simultaneously stained within the same tube to detect
sIgM expression and soluble DC-SIGN binding (n 5 6).
Analysis (FlowJo) of singlet live cells initially allowed ex-
amination of sIgM expression (A). Populations positive for
sIgM were gated to determine DC-SIGN binding on these
cells. (B) Representative FACS plot of a control experi-
ment to show that recombinant DC-SIGN-Fc binding is
not affected by AT10 (anti-CD32) antibody or by the
FcR-blocking reagent. (C) Analysis of GeoMFI data
(GraphPad Prism) found that expression of sIgM was
significantly correlated to binding of DC-SIGN (Spearman
rank test). This correlation was confirmed further within
samples of FL cells showing double peaks of high and low
sIgM expression.
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a similar kinetic being maximal at the 6-hour time point. Data from 11
samples conﬁrmed a signiﬁcant increase inMYC levels after exposure
to DC-SIGN (Figure 5B).
In contrast, normalBcells did not upregulateMYCafter exposure to
DC-SIGN, but did after bead-bound anti-Ig (Figure 5C). The potential
relevance of this upregulation in vivo was investigated by staining of
FL tissue forMYCprotein.Weanalyzed2cases of classical FL for each
of the grades 1, 2, and 3a, as well as 2 control reactive lymphoid tissues
(data not shown). MYC protein was detectable in a small fraction of
cells in all FL cases. Immunohistochemistry of a representative FL case
(grade 2) revealed FL cells, with characteristic size range and hetero-
geneous neoplastic cell nuclei, embedded within the CD211 follicular
dendritic cell network, among which were detectable MYC1 FL cells
(supplemental Figure 6). Although numbers of cells are small, MYC
is a highly regulated protein, so expression would be expected to
be limited.
Effects of incubation in vitro on expression of sIg or CXCR4
Levels of sIg for FL cells vary but are in the same range as normal
memory B cells4 (Figure 1A) and are ;10 times higher than cells
of chronic lymphocytic leukemia (CLL). In CLL, expression of
sIgM can be reversibly downregulated in vivo by antigen or in vitro
by anti-Ig.16 A second receptor with reversible downregulated
expression in CLL is the chemokine receptor, CXCR4.17-20 To in-
vestigate potential in vivo downregulation in FL cells, expression
of sIg and CXCR4 was tracked over time in vitro in 9 FL samples
(6 IgM1, 3 IgG1). Only 1 of 9 showed any recovery of sIg expression,
even when starting levels were relatively low (Figure 6A-B). In con-
trast, most cases (8/9) recovered expression of CXCR4 over a 24-hour
period (Figure 6C-D). The high expression of sIg and its stability
in vitro argue against downregulation of sIg by antigen in vivo.
Recovery of CXCR4 expression reveals that the FL cells were able
to reverse the expected chemokine-mediated downmodulation in
tissue sites.
Engagement of sIg by DC-SIGN fails to lead to endocytosis
After binding of anti-Ig, sIg ofCLLcells undergoes rapid endocytosis.16
The ability of DC-SIGN to induce endocytosis of sIg was ﬁrst tested
by measuring the sIgM remaining at the cell surface after incubation
with either DC-SIGN or with anti-Ig. Endocytosis was clearly seen
after exposure to anti-IgM as expected in both FL cells (Figure 7A)
and normal B cells (Figure 7B) after incubation for 10 to 30 minutes.
Efﬁcient removal of sIg was checked using an FITC-labeled sec-
ondary anti-goat (Fab9)2 antibody. Assessment of the effects of en-
gagement with DC-SIGN on sIgM expression has to take into account
a partial blocking of access of anti-IgM by bound DC-SIGN.4 The
initial level of DC-SIGN–engaged sIgM in ice was then assigned
a value of 100%. No signiﬁcant change in this level was detectable
after incubation for 60 minutes (Figure 7C), indicating minimal re-
moval by endocytosis. To increase lectin avidity, a crosslinking
Figure 3. Induction of FL-specific signaling pathways by DC-SIGN. Western blotting demonstrating ERK and AKT phosphorylation in primary FL cells taken from sIgM1
and sIgG1 cases. Representative examples of 16 samples: (A) sIgM1 and (B) sIgG1 cases treated with soluble or bead isotype control (IC), DC-SIGN, or anti-Ig for 0.5 and
3 hours. (C) Fold change analysis was used to measure the extent of ERK and AKT phosphorylation induced in the 16 samples by either DC-SIGN or anti-Ig over time.
(D) Normal B cells were stimulated with either DC-SIGN or anti-IgM beads, and western blotting analysis was done for ERK and AKT phosphorylation.
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secondary antibody against Fcg was added to the DC-SIGN protein
before addition to the cells. Even then, no signiﬁcant endocytosis could
be induced (Figure 7D).
To test whether binding of DC-SIGN, which failed to induce
endocytosis, was sufﬁcient to induce a signal, we analyzed 2 FL
samples (FL86 and FL590) in depth. The results were very similar and
Figure 4. Downstream signaling induced by anti-Ig or DC-SIGN is ablated by kinase inhibitors. PhosFlow data analysis to examine phosphorylation of PLCg2 and
ERK in FL cells. Cells were pretreated with H2O2 to inhibit phosphatases before stimulation with either crosslinked DC-SIGN (xDC-SIGN) or soluble anti-Ig. (A) Cytobank
software (representative heat map traces shown) was used to measure phosphorylation of PLCg2 and ERK for each treatment at each time point. (B) Fold-change
analysis was used to chart the level of phosphorylation over time in 13 samples tested. (C) PhosFlow was used to measure the impact of the SYK inhibitor tamatinib or
BTK inhibitor ibrutinib on phosphorylation of PLCg2 and ERK. Analysis of data for 9 samples (6 for SYK and 3 for BTK) was compiled (GraphPad Prism) (Student t test;
****P , .0001).
Figure 5. DC-SIGN treatment induces MYC expres-
sion in FL cells. Comparison of the ability of DC-SIGN
to upregulate MYC in primary FL cells in relation to
anti-Ig stimulation. (A) Western blotting was used to
measure MYC protein expression in FL cells treated
with isotype control, DC-SIGN, or anti-Ig beads over
time (2 representative samples shown). (B) Fold-change
analysis of band densitometry was used to compare MYC
expression induced by each treatment of 11 FL samples
tested (Student t test). (C) Western blotting was used to
examine MYC expression in normal B cells treated with
either DC-SIGN or anti-IgM beads over time.
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are illustrated for FL86 in supplemental Figure 6. After exposure to
DC-SIGN,wemeasured binding, signaling, andpersistence of sIgMon
the cell surface (supplemental Figure 6A). It is clear that binding of
DC-SIGN was high (supplemental Figure 6B) and was able to mediate
phosphorylation of ERK1/2 and especially AKT (supplemental
Figure 6C). However, there was no signiﬁcant loss of expression of
sIgM (supplemental Figure 6D) by endocytosis. Comparison of
endocytosis estimated by reduction of expression of sIgM at 30
minutes indicated a ;77% reduction via anti-IgM, but only
a ;29% reduction via DC-SIGN.
Figure 6. FL cells do not increase expression of
surface Ig after incubation in vitro. Recovery of
surface marker expression of FL samples in vitro
(n 5 9; 6 IgM1; 3 IgG1). FACS was used to determine
expression (GeoMFI) of surface Ig for both (A) IgM-
positive and (B) IgG-positive patients along with expres-
sion of CXCR4 (C and D) at zero time and at subsequent
intervals up to 72 hours. Expression analysis of GeoMFI
(CellQuest) was used to plot change of expression over
time.
Figure 7. DC-SIGN fails to induce endocytosis of
surface Ig by FL cells. Analysis of surface IgM
internalization in response to DC-SIGN or anti-IgM treat-
ments. Primary FL or normal B cells were treated on
ice for 45 minutes with either soluble anti-IgM F(ab9)2
or DC-SIGN before incubation at 37°C to allow inter-
nalization. Flow cytometry was used to determine surface
IgM expression over time in relation to zero time (100%).
(A) FL samples treated with anti-IgM. (B) Normal B cells
treated with soluble anti-IgM. (C) FL samples treated with
soluble DC-SIGN. (D) FL cells treated with cross-linked
(x) DC-SIGN. Expression of sIgM determined by FACS
was analyzed using CellQuest.
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Localization of DC-SIGN in FL lymph node
Expression of DC-SIGN in FL lymph node was assessed by immu-
nohistochemistryusinganti-CD209.The results (supplementalFigure7)
show a background of CD201 FL cells with sinusoidlike structures
staining forCD209.Therewere also somemononuclear cells (arrows)
that were CD2091.
Discussion
NormalBcells donot linger in theGC,but go througha ruthless process
of antigen selection or death. Selected B cells leave the site and, al-
though revisiting does occur,21 their fate is to become memory B cells
or plasma cells. In contrast, FL cells remain mainly locked in the GC,
partially protected by upregulated BCL-2, and are apparently able to
exploit themicroenvironment for survival and proliferation.Candidate-
supporting cells are likely to be multiple, but appear to include
IL-4–producing T-follicular helper cells, tumor-associated macro-
phages, and stromal cells.22
The distribution and number of macrophages varies in FL, but an
overall increase has been associated with a poorer prognosis.23,24 One
problemof assessing aprognostic role is that pathogenesis and response
to therapy both inﬂuence clinical outcome, possibly in opposite di-
rections. Thus macrophages may promote tumor growth but, as medi-
ators of antibody-dependent cellular cytotoxicity, they are required for
antibody therapy.25
The positively selected expression of high mannose in the sIg var-
iable regions is a clue to pathogenesis,26 and strongly indicates an es-
sential interaction with a presumed lectin in the lymph node. It appears
that mannosylation motifs are acquired at the early stage of lympho-
magenesis, termed “follicular lymphoma in situ.”27 Although we cannot
be certain which lectin is involved, we have used DC-SIGN, known
to recognize mannoses both on pathogens and on self-ligands,11 as a
paradigm to probe the consequences of engaging the mannosylated sIg.
It is clear that DC-SIGN can activate intracellular phosphorylation
pathways characteristic of sIg engagement, thereby offering a mecha-
nism for antigen-independentB-cell receptor signaling inFL.However,
in contrast to anti-Ig, DC-SIGN, even when multimerized, fails to
induce endocytosis. This is consistent with the ﬁnding that FL cells,
unlike CLL cells, show no evidence for downregulation of sIg in vivo
or for the anergic phenotype characteristic of CLL. CLL cells have
features of cells that reversibly engage antigen in vivo, apparently
leading to endocytosis followed by recovery.16 Because the antigen
may be cell-bound,28 CLL cells appear capable of “biting” it off cell
surfaces as described for normalBcells.29Noneof this occurs inFL, but
sIg expression remains essential, as does the upregulation of BCL-2.
One possibility is that interaction with a lectin could provide a con-
tinuous low-level activatory signal for tumor cells.
Expression of DC-SIGN in FL tissue from our cases conﬁrms
a dominating high level on lymphatic sinusoidal structures27 but also
indicates expression on other nearby mononuclear cells. Because IL-4
is detected in LN tissue, polarization to the M2 type occurs22 and
DC-SIGN is upregulated.30 The situation in vivo is more complex.
FL cells could encounter DC-SIGN–expressing macrophages as they
crawl through the tissue, or the DC-SIGN on lymphatic endothelium
could bind FL cells and block egress, acting as a retention signal. Both
adhesion and the signaling pathways activated in vitro were blocked
by inhibitors of BTK or SYK. However, although it is likely that con-
tinuous stimulation by local autolectins is vital,we have recently shown
that lectins from certain bacteria can also induce an i[Ca21] ﬂux,31
raising the possibility of tumor perturbation during infection.
The ability of receptor-associated glycan to modulate signaling
pathways has been revealed by the effects of galectins on T or B
lymphocytes.32 In that case, binding of galectin to galactose residues on
the receptors generates a “lattice” that affects oligomerization and sig-
naling but prevents endocytosis.33 It appears likely that a parallel array
of lectins can target V-region mannoses in sIg and that FL cells have
exploited this strategy for survival and proliferation. Opportunities for
blocking this interaction include either antibodies against high man-
noses, which are being developed for targeting HIV,34 or potentially
the clinical-grade galactomannans, aimed to release tumor-inﬁltrating
lymphocytes fromgalectin-mediated suppression inpatientswith cancer.35
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